Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses
Reuters
Sep 05
Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses
Capricor Therapeutics Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi & Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.